EUVIMEDEUVIMED entdecken
Crossref

Variant Acid β-Glucosidase and Gaucher disease

Kathleen A. Cornely, Roderico Acevedo, Kristen Procko

QUBES · 24.07.2026

DOI: 10.25334/jgjw-j640 ↗

Kurz gefasst

Fachartikel in der Zeitschrift QUBES, erschienen am 24.07.2026. Verfasst von Kathleen A. Cornely und 2 weiteren Autor:innen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

lt;pgt;lt;a href=quot;https://molecular-casenet.rcsb.org/node/56quot;gt;lt;span class=quot;field field--name-title field--type-string field--label-hidden quickedit-fieldquot; data-quickedit-field-id=quot;node/56/title/en/fullquot;gt;Variant Acid amp;beta;-Glucosidase and Gaucher diseaselt;/spangt;lt;/agt;lt;/pgt; lt;pgt;lt;span id=quot;docs-internal-guid-9cfc066f-7fff-cb24-2c33-7798ef625061quot; style=quot;font-size:11pt;font-family:Arial,sans-serif;color:#000000;background-color:transparent;font-weight:400;font-style:normal;font-variant:normal;text-decoration:none;vertical-align:baseline;white-space:pre;white-space:pre-wrap;quot;gt;lt;emgt;Overviewlt;/emgt;: Gaucher disease is a genetic disease involving a mutation in the acid lt;/spangt;lt;span style=quot;font-size:11pt;font-family:#039;Noto Sans Symbols#039;,sans-serif;color:#000000;background-color:transparent;font-weight:400;font-style:normal;font-variant:normal;text-decoration:none;vertical-align:baseline;white-space:pre;white-space:pre-wrap;quot;gt;amp;beta;lt;/spangt;lt;span style=quot;font-size:11pt;font-family:Arial,sans-serif;color:#000000;background-color:transparent;font-weight:400;font-style:normal;font-variant:normal;text-decoration:none;vertical-align:baseline;white-space:pre;white-space:pre-wrap;quot;gt;-glucosidase enzyme, a hydrolase required for the degradation of glucosyl ceramides in the lysosomes. The inability to degrade glucosyl ceramides leads to their build up in the spleen, liver, lungs, bones, and brain, which causes the symptoms observed in these patientsamp;mdash;enlarged liver and spleen, liver malfunction, skeletal disorders, and neurological complications. A study of the acid lt;/spangt;lt;span style=quot;font-size:11pt;font-family:#039;Noto Sans Symbols#039;,sans-serif;color:#000000;background-color:transparent;font-weight:400;font-style:normal;font-variant:normal;text-decoration:none;vertical-align:baseline;white-space:pre;white-space:pre-wrap;quot;gt;amp;beta;lt;/spangt;lt;span style=quot;font-size:11pt;font-family:Arial,sans-serif;color:#000000;background-color:transparent;font-weight:400;font-style:normal;font-variant:normal;text-decoration:none;vertical-align:baseline;white-space:pre;white-space:pre-wrap;quot;gt;-glucosidase enzyme, involving the construction of mutants, and of small molecule inhibitors, leads to a greater understanding of how the enzyme works, and can also lead to the development of therapeutic agents to treat the disease. Inhibiting an enzyme with decreased function may seem counterintuitive as a treatment strategy, but research has shown that these compounds can bind to a mutated enzyme and act as molecular chaperones, shepherding the enzyme to the lysosome (where the inhibitor dissociates at the low pH), resulting in an increased amount of enzyme delivered to the lysosome. lt;/spangt;lt;/pgt; lt;pgt;lt;span style=quot;font-size:11pt;font-family:Arial,sans-serif;color:#000000;background-color:transparent;font-weight:400;font-style:normal;font-variant:normal;text-decoration:none;vertical-align:baseline;white-space:pre;white-space:pre-wrap;quot;gt;lt;emgt;Molecules exploredlt;/emgt;: lt;/spangt;lt;span id=quot;docs-internal-guid-c078a41c-7fff-d3c1-4b24-887747314599quot; style=quot;font-size:11pt;font-family:Arial,sans-serif;color:#000000;background-color:transparent;font-weight:400;font-style:normal;font-variant:normal;text-decoration:none;vertical-align:baseline;white-space:pre;white-space:pre-wrap;quot;gt;amp;nbsp;The primary molecule examined in this case study is acid lt;/spangt;lt;span style=quot;font-size:11pt;font-family:#039;Noto Sans Symbols#039;,sans-serif;color:#000000;background-color:transparent;font-weight:400;font-style:normal;font-variant:normal;text-decoration:none;vertical-align:baseline;white-space:pre;white-space:pre-wrap;quot;gt;amp;beta;lt;/spangt;lt;span style=quot;font-size:11pt;font-family:Arial,sans-serif;color:#000000;background-color:transparent;font-weight:400;font-style:normal;font-variant:normal;text-decoration:none;vertical-align:baseline;white-space:pre;white-space:pre-wrap;quot;gt;-glucosidase. Visualization of this enzyme with small molecule inhibitors bound leads to a greater understanding of the important intermolecular interactions involved between the inhibitor and the enzyme.lt;/spangt;lt;/pgt;

Schlagwörter

Gaucher diseaseglucocerebrosidaselysosomal storage diseaselysosomeslysosomal enzymes

Zitieren

APA

Cornely, K. A., Acevedo, R., & Procko, K. (2026). Variant Acid β-Glucosidase and Gaucher disease. QUBES. https://doi.org/10.25334/jgjw-j640

Vancouver

Cornely KA, Acevedo R, Procko K. Variant Acid β-Glucosidase and Gaucher disease. QUBES. 2026. doi:10.25334/jgjw-j640

BibTeX
@article{Cornely2026,
  author = {Cornely, Kathleen A. and Acevedo, Roderico and Procko, Kristen},
  title = {Variant Acid β-Glucosidase and Gaucher disease},
  journal = {QUBES},
  year = {2026},
  doi = {10.25334/jgjw-j640}
}
Kostenlos starten →